Published in Cardiovascular Device Liability Week, May 7th, 2006
The jury also awarded a compensatory award to a second plaintiff. The trial is continuing into the punitive phase for the second plaintiff. Merck will present evidence it believes shows that the company submitted to the U.S. Food & Drug Administration all relevant and material information concerning Vioxx. Merck will make further statements after the jury completes its deliberations after this phase of the trial.
Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Device Liability Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.